Nationwide “Hospital Emergent Capability Accreditation by Level-Stroke” Improves Stroke Treatment in Taiwan.
- Author:
Tain Junn CHENG
1
;
Giia Sheun PENG
;
Wei Siang JHAO
;
Jiunn Tay LEE
;
Tsung Hsi WANG
Author Information
- Publication Type:Original Article
- Keywords: Ischemic stroke; Thrombolysis; Tissue-type plasminogen activator; Hospital Emergent Capability Accreditation by Level-Stroke; Taiwan
- MeSH: Accreditation*; Humans; Outcome Assessment (Health Care); Stroke*; Taiwan*; Tissue Plasminogen Activator
- From:Journal of Stroke 2017;19(2):205-212
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND AND PURPOSE: Recombinant tissue plasminogen activator (rtPA) is one of the proven therapies that improve the outcome of patients with acute ischemic stroke (AIS). In 2009, the Ministry of Health and Welfare, Executive Yuan, Republic of China, launched the project “Hospital Emergent Capability Accreditation by Level-Stroke (HECAL-Stroke)” to improve AIS treatment in Taiwan. The current study was performed to determine whether the project launched by the government was effective in promoting rtPA therapy among AIS patients. METHODS: All participating hospitals were verified and designated as “heavy duty (HD),”“moderate duty (MoD),” or “medium duty (MeD)” according to the stroke center criteria. Four annual indices (rates of treatment, protocol adherence, in-time treatment, and complications) were recorded from 2009 to 2014 as outcome measures. The data were analyzed using the χ² test for significance. RESULTS: The number of certified hospitals progressively increased from 74 to 112 during the 6-year period and finally consisted of 33 HD, 9 MoD and 70 MeD hospitals in 2014. The annual intravenous rtPA treatment rate increased significantly from 3.0% in 2009 to 4.5% in 2014. The protocol adherence rates were 95.7% in the HD group, 92.4% in the MoD group and 72.8% in the MeD group. The annual in-time treatment rate significantly improved from 26.0% in 2009 to 60.1% in 2014. The overall symptomatic intracranial hemorrhagic rate after rtPA treatment was 8.6%. CONCLUSIONS: Initiation of the HECAL-Stroke project by the government significantly improved rtPA treatment in Taiwan.
